-+ 0.00%
-+ 0.00%
-+ 0.00%

VivoSim Labs Enters Seven-Figure Agreement With A Top-10 Global Pharmaceutical Company For Its NAMkind Testing Services; Company Expects FY27 Revenue To Exceed Prior Guidance Of 500%+ Growth

Benzinga·11/19/2026 13:07:23
Listen to the news

The agreement covers NAMkind™ liver and intestinal toxicology testing, with work already underway. Revenue under the agreement is expected to be recognized in VivoSim’s fiscal Q3 and Q4, ending Dec. 31 and March 31, respectively.
After this program, VivoSim anticipates that NAMkind™ testing will become part of the Customer's regular flow of ongoing preclinical work.
The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 12, shows growth in both its liver toxicology and intestinal toxicology businesses.
Growth came from both large pharma and smaller customers. Other current and future customers are also expected to move toward full integration of NAMkind™ testing into their workflows


How a Large Customer Adopts a New Test

A large pharmaceutical company (>$10B in annual revenue) does not quickly change how it tests drug candidates and requires extensive scientific due diligence to consider this kind of agreement. It then runs a new model on compounds whose clinical outcomes it already knows, compares the results with what its animal studies showed, and only then commits live program work. The agreement announced today covers that program work. Once it is complete, the Company anticipates that the Customer's compounds will come to VivoSim as the Customer's programs reach the relevant decision point, rather than as one-off studies.